Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
27 mars 2024 16h01 HE
|
Celcuity Inc.
Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer Presented nonclinical data...
CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)
19 mars 2024 10h00 HE
|
Charm Therapeutics
PRESS RELEASE CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) LONDON – 19 March 2024 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research company...
Global Astaxanthin Market Size is projected to reach USD 7,536.19 million by 2031, growing at a CAGR of 16.78%: Straits Research
13 mars 2024 09h10 HE
|
Straits Research Private Limited
New York, United States, March 13, 2024 (GLOBE NEWSWIRE) -- Astaxanthin is produced by the yeast fungus Xanthophyllomyces dendrorhous and the freshwater microalgae Haematococcus Pluvialis....
How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay?
12 mars 2024 15h10 HE
|
Spherix Global Insights
EXTON, PA, March 12, 2024 (GLOBE NEWSWIRE) -- For neurologists tasked with delivering the distressing diagnosis of Amyotrophic Lateral Sclerosis (ALS) or Alzheimer’s Disease (AD), the upcoming...
Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma
11 mars 2024 07h00 HE
|
Replay Bio
Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma Phase 1/2 clinical study of NY-ESO-1 TCR/IL-15 NK for relapsed...
NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial
07 mars 2024 07h00 HE
|
NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial Brain-penetrant NLRP3 inflammasome inhibitor...
Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024
07 mars 2024 04h00 HE
|
Oxford BioTherapeutics
OGAP®-Verify allows for significantly enhanced sensitivity and specificity for improved target selection, dramatically accelerating drug target discoveryOGAP-Verify is now more sensitive than...
Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain
07 mars 2024 03h00 HE
|
Persica Pharmaceuticals
Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain London, UK, 07 March 2024 – Persica Pharmaceuticals Ltd, a privately held,...
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
05 mars 2024 16h30 HE
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced an oral...
Pharmacogenomics Market is Expected to Reach $5.8 Billion | MarketsandMarkets™
04 mars 2024 07h30 HE
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, March 04, 2024 (GLOBE NEWSWIRE) -- Pharmacogenomics market in terms of revenue was estimated to be worth $3.5 billion in 2023 and is poised to reach $5.8 billion by 2028, growing at a CAGR...